Background: Kratom (Mitragyna speciosa Korth) use has increased in Western countries, with a rising number of associated deaths. There is growing debate about the involvement of kratom in these events. Aims: This study details the characteristics of such fatalities and provides a 'state-of-the-art' review. Methods: UK cases were identified from mortality registers by searching with the terms 'kratom', 'mitragynine', etc. Databases and online media were searched using these terms and 'death', 'fatal*', 'overdose', 'poisoning', etc. to identify additional cases; details were obtained from relevant officials. Case characteristics were extracted into an Excel spreadsheet, and analysed employing descriptive statistics and thematic analysis. Results: Typical case characteristics (n = 156): male (80%), mean age 32.3 years, White (100%), drug abuse history (95%); reasons for use included self-medication, recreation, relaxation, bodybuilding, and avoiding positive drug tests. Mitragynine alone was identified/implicated in 23% of cases. Poly substance use was common (87%), typically controlled/recreational drugs, therapeutic drugs, and alcohol. Death cause(s) included toxic effects of kratom ± other substances; underlying health issues. Conclusions: These findings add substantially to the knowledge base on kratom-associated deaths; these need systematic, accurate recording. Kratom's safety profile remains only partially understood; toxic and fatal levels require quantification.
Introduction
Kratom (Mitragyna speciosa Korth) is a tree native to South East Asia (especially Malaysia, Thailand and Indonesia), New Guinea and the Philippines. It typically grows to between 4 and 16 m in height. (Mis)use of kratom appears to have increased in Western countries over the past decade, with a growing number of deaths being reported as associated with this plant and synthetic forms of its active ingredients mitragynine and 7-hydroxymitragynine (figures 1 and 2). Some context is provided, through means of a 'state-of-the-art review' (Grant and Booth, 2009) , against which these deaths can be understood. This paper outlines the principal characteristics of decedents and the fatalities related to kratom use. Furthermore, it discusses the implications of the ways in which these cases are identified, reported, recorded and interpreted.
Overview of the state of knowledge of kratom

Chemistry and pharmacology
Amongst the psychoactive ingredients found in kratom leaves is the alkaloid mitragynine and its main metabolite 7-hydroxymitragynine. Mitragynine was first isolated in Edinburgh in 1921 (Chemist and Druggist, 1930) . These molecules bind to the µ (mu), κ (kappa) and δ (delta) opioid receptors (Holler et al., 2011; Prozialeck et al., 2012) , acting as an agonist at all three receptors, and as an antagonist at the δ receptor (Kruegel et al., 2016; Váradi et al., 2016 ). An in vivo mice study demonstrated that mitragynine acts as an antagonist on the serotonin and noradrenaline receptor systems (Matsumoto et al., 1996) .
It is reported that 7-hydroxymitragynine has a potency 13-times higher than morphine (Takayama, 2004) and 46 times that of mitragynine (Matsumoto et al., 2004; Shellard et al., 1978) . Kratom's pharmacological properties are affected by where, when and how it is cultivated. Plants from Indonesia contain higher levels of mitragynine and related alkaloids than those from Malaysia and Thailand (Orio et al., 2012) . Kratom varieties with red-veined leaves (only found in Thailand) are reported to be more sedating than those with green or white leaves, which are more stimulating, according to drug user fora (Domingo et al., 2017) .
The approximate mitragynine content of fresh kratom leaves is 0.86 mass % compared to 0.026 mass % for 7-hydroxymitragynine (Ponglux et al., 1994) . Levels of mitragynine and 7-hydroxymitragynine in kratom products are in the range of 1.5-2 mass % and about 0.02-0.33 mass % respectively Lydecker et al., 2016) . So, the concentration of mitragynine is 50-100 times that of its hydroxy metabolite (Kruegel and Grundmann, 2018) .
A typical 8 g dose of raw kratom may mean that a 70 kg individual is exposed to 120-180 mg of mitragynine and 1.1-3.4 mg of 7-hydroxymitragynine (1.2-2.5 mg/kg and 0.015-0.048 mg/kg respectively) (Kruegel and Grundmann, 2018) . Full effects are usually apparent 30-60 min after oral consumption but onset may be felt within 10-20 min. Kratom's effects can last 5-7 h, being strongest 2-4 h after ingestion; weak effects can be felt up to a day later Prozialeck et al., 2012; Rosenbaum et al., 2012; Scott et al., 2014 ).
Metabolism and pharmacokinetics
There are few human studies of mitragynine and 7-hydroxymitragynine pharmacokinetics. Trakulsrichai et al. (2015) suggest a two-compartment model of metabolism for mitragynine. Following oral consumption, the half-lives of mitragynine and 7-hydroxymitragynine are about 3.5 and 2.5 h respectively (Henningfield et al., 2018) . Both are eliminated primarily in urine (Neerman et al., 2013; Prozialeck et al., 2012) . Absolute bioavailability is about 3% for mitragynine (Parthasarathy et al., 2010) . However, this would not appear to be explained by either a high first-pass metabolism or poor gastro-intestinal absorption (Kruegel and Grundmann, 2018) . Blood levels of mitragynine of up to 191 ng/mL after consumption of tea containing 104, 166 and 192 g/mL of kratom over 7 days were recorded in 10 chronic users of kratom (Trakulsrichai et al., 2015) . The median lethal dose (LD 50 ) levels for mitragynine in rodent studies have been reported as 200 mg/kg in a rat (Janchawee et al., 2007) and 477 mg/kg for mice (Sabetghadam et al., 2013 ). It appears that the LD 50 levels for Swiss Webster male rats is similar for intravenous (IV) mitragynine (27.8 mg/kg), 7-hydroxymitragynine (24.7 mg/kg), and heroin (23.7 mg/kg), whereas the LD 50 level for oral mitragynine in the same animals is 547.7 mg/kg (Smith et al., 2019) .
Availability, routes of administration and usage
Mitragynine is insoluble in water but can be dissolved using a range of conventional organic solvents such as acetic acid, acetone, chloroform, diethyl ether and alcohols (European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2015a). The dried leaves can also be consumed as a tea or smoked (Hassan et al., 2013) . According to consumers, the amount of leaves that constitutes a typical dose cannot easily be smoked (Cinosi et al., 2015) . Products derived from kratom are typically found as crushed or powdered leaves. Some powder preparations, green or beige-brown in colour, have additional leaf extracts added. Paste-like extracts and dark brown resin can be prepared by boiling off the water from aqueous leaf suspensions. These can be added to finely chopped palm leaves and made into pills or smoked in pipes as 'madatin' (Azizi et al., 2013) . Alternatively, extracts can be added to hot water and then consumed alone or added to herbal teas to make it more acceptable -'toss and wash' (Cinosi et al., 2015; Hanapi et al., 2013) . Small pellets, capsules or paper 'bombs' filled with kratom powder are also available for oral ingestion. In the USA the most popular modes of consumption are powdered form with a beverage, pill, pure powder or as a tea (Grundmann, 2017) . Other users prefer to take kratom with food, making cookies or mixing it with yoghurt to counteract its bitter taste (Cinosi et al., 2015) . More recently, evidence has emerged of intravenous injecting of kratom (Lydecker et al., 2017) . Kratom extracts (tinctures) are now available for use in vapourisers (Abayarathna and Jaehne, 2016; Poklis et al., 2017) .
Tinctures and drinks, including alcohol and/or other psychoactive substances, can be purchased. Common additions in South East Asia are cough syrups containing codeine or diphenhydramine to which are added a caffeine-based soft drink, and an anti-depressant, an anxiolytic or an analgesic (EMCDDA, 2015a; Tungtananuwat and Lawanprasert, 2010) : an example in Thailand and Malaysia is the '4 × 100' cocktail (Tanguay, 2011; Tungtananuwat and Lawanprasert, 2010) , which is believed to have more intoxicating effects (Chongrattanakon et al., 2017) . In other contexts and/or regions a variety of both 'traditional' recreational substances (e.g. alcohol, amphetamines, benzodiazepines, cannabis, cocaine, hallucinogens, methadone and paracetamol) and new/novel psychoactive substances (NPS) such as kava, synthetic cathinones, phenethylamines and tryptamines are also taken with kratom products/ingredients (Anwar et al., 2016; Cinosi et al., 2015) .
As with other 'herbal' products, consumers of kratom or related derivatives, whether purchasing online or from other outlets, need to be aware that there is not only variability in the concentrations of kratom, but also the potential for such products to contain very dangerous/potent ingredients such as O-desmethyltramadol (Scott et al., 2014) . However, Griffin et al. (2016) found that products marketed as liquid pain relief and containing mitragynine contained kratom. It is also worth noting that the concentrations of 7-hydroxymitragynine found in products may be artificially made considerably higher than those found in kratom leaves (Lydecker et al., 2016 ).
There appears to be a dose-response effect: 1-5 g of leaves (a low to moderate dose) generate mild stimulant effects that reportedly enable workers in Thailand and other South East Asia regions to stave off fatigue (Cinosi et al., 2015; Prozialeck et al., 2012) , as well as having recreational effects such as creating a perception of being more alert, 'entactogenic' effects like empathy and euphoria, and sometimes increasing sexual arousal (Cinosi et al., 2015) . A 5-15 g (moderate to high) dose of leaves produces opioid-like effects, which has been employed to not only manage pain, diarrhoea, and opioid withdrawal symptoms but also for euphoriant effects. Over 15 g (a very high dose) often gives rise to sedative effects, inducing intoxication (Prozialeck et al., 2012) , and causes opioid-like analgesic effects, as well as causing users to be 'less sensitive to physical or emotional pain, to feel and look calm, and to have a general feeling of comfortable pleasure … Others report an increase of empathy feelings' (Cinosi et al., 2015) . Boyer et al. (2008) note that as early as the 1830s, kratom was reported as being used as a substitute for opiates.
Addiction potential
There are case reports from South East Asia, Europe and the USA of chronic kratom use leading to tolerance, cross-tolerance to both kratom and opiates, physical dependence/addiction, craving and withdrawal problems (Adkins et al., 2011; Assanangkornchai et al., 2007; Babu et al., 2008; Boyer et al., 2008; Cinosi et al., 2015; McWhirter and Morris, 2010; Roche et al., 2008; Saingam et al., 2013; Suwanlert, 1975) . Whilst some users report low craving, others experience difficulty in abstaining (Ahmad and Aziz, 2012; Singh et al., 2015) . Kratom tolerance develops slower than for morphine and has lower potential for addiction (Váradi et al., 2016) . As with opioids, neonatal abstinence syndrome has been described in some cases (Davidson et al., 2019; Eldridge et al., 2018; Mackay and Abraham, 2018; Murthy and Clark, 2019; Trakulsrichai et al., 2013) . The addiction potential of kratom and its main alkaloids is still controversial in the scientific community and on discussion websites (Hassan et al., 2013) , but mitragynine probably merits further investigation in respect of its potential for use in opioid dependence (Yue et al., 2018) and chronic pain relief. It may be that mitragynine rather than 7-hydroxymitragynine is more suited for such uses (Hemby et al., 2018) because of the former's lower abuse potential.
Withdrawal symptoms are similar to those described for traditional opioids but are milder (Singh et al., 2014 (Singh et al., , 2016 and overlap in terms of side-effects, including decreased appetite, anorexia, weight loss, decreased sexual drive, insomnia, myalgia (muscle spasms and pain), arthralgia (aching in the muscles and bones), jerky movement of the limbs, watery eyes/nose, rhinorrhoea, dry mouth, hot flushes, hypertension, fever, nausea, frequent micturition, and diarrhoea (Burkill and Haniff, 1930; Cinosi et al., 2015; Hassan et al., 2013; Singh et al., 2014; Stanciu et al., 2019) . Most of these effects appear to be dose-dependent (Grundmann, 2017; Smith and Lawson, 2017) . Psychological withdrawal symptoms commonly reported are dysphoria, nervousness, restlessness, tension, anger, hostility, irritability, aggression, and sadness (Singh et al., 2014; Suwanlert, 1975) . Psychotic symptoms such as mental confusion, delusion, and hallucination are reportedly caused by regular use of kratom (Suwanlert, 1975) . On the other hand, a recent small-scale study appears to show that long-term use by regular kratom users does not impair motor, memory, attention or executive function (Singh et al., 2019) . One recent US study reported that about two-fifths (42.6%) of users reported some form of withdrawal symptoms (Grundmann, 2017) .
Adverse effects of using kratom
Common side-effects reported include decreased appetite, anorexia, weight loss, temporary erectile dysfunction, insomnia, sweating, hyperpigmentation, hair loss, tremor, and constipation (Cinosi et al., 2015) . The commonest symptoms reported in the USA are tachycardia (25.0%); agitation/irritability (23.8%); drowsiness (19.4%); nausea (14.7%); and hypertension (11.7%) (Anwar et al., 2016) . These symptoms, together with anxiety, are reported by other researchers (Prozialeck et al., 2012; Singh et al., 2014; Swogger et al., 2015) . Kratom appears capable of raising prolactin levels leading to secondary hypogonadism (LaBryer et al., 2018) . Chronic use can also cause elevated levels of transaminases (Carter et al., 2016) .
Reported adverse effects, following high doses and/or the use of concentrated extracts, include tachycardia (Lu et al., 2014) , intrahepatic cholestasis (Griffiths et al., 2018; Kapp et al., 2011; Riverso et al., 2018) , hepatitis (including cholestatic) and liver toxicity (Dorman et al., 2015; Drago et al., 2017; Forrester, 2013; Kupferschmidt, 2011) , seizure and coma (Nelsen et al., 2010; Pantano et al., 2016; Roche et al., 2008) , Adult Respiratory Distress Syndrome (Jaliawala et al., 2018; Pathak et al., 2014) , and hypothyroidism (Sheleg and Collins, 2011) . Repeated kratom use can lead to generalised tonic-clonic seizures and possible structural brain lesions and symptomatic focal epilepsy (Tatum et al., 2018) . Cerebral haemorrhage following the use of kratom by an intravenous heroin user in remission has been reported (Liss et al., 2016) .
Epidemiology
Information on the epidemiology of kratom use is scarce, due, in part, to the absence of robust metrics on typical doses, regularity of use, etc. Most information on kratom prevalence relates to its use in Thailand where it is used as a self-medicating substance to treat opiate/opioid dependence, and as an opium substitute in Malaysia (Ahmad and Aziz, 2012 (Wonguppa and Kanato, 2017) ; in the year prior to the survey use was 2.1% and 0.7% respectively. The consumption of the cocktail appears to have been causing concern in official circles for several years, especially in the Thailand/ Malaysia border regions (Chang Rai Times, 2012) . Facebook pages in Thai are typically positive or neutral towards kratom rather than negative in tone (Thaikla et al., 2018) .
Misuse of kratom has increased in Western countries in recent years. Internet surveys conducted by the EMCDDA in 2008 indicated that kratom was one of the most widely offered 'legal highs' in 44% of the 27 European online shops investigated (Hillebrand et al., 2010) . A more extensive EMCDDA Internet survey in July 2011 showed that kratom was the most widely offered product with 128 out of 631 (20%) of online retailers shipping it to the EU (EMCDDA, 2011). An Internet snapshot carried out in the UK in April 2009 showed that among the 346 unique products offered by 39 shops, kratom (n = 30) was second only to Salvia divinorum (Schmidt et al., 2011) . Kratom products can be bought from 'head', 'smart' and 'herbal' shops and increasingly online from overseas (Cinosi et al., 2015) . The latter sources are likely to be based in Indonesia, for example, 'Bali Kratom' where it is not controlled. The Internet is being increasingly used as a means of sourcing kratom for those using it for self-medication purposes Cinosi et al., 2015; EMCDDA, 2015a) . The principal reasons for this self-medication are (a) to manage opioid withdrawal by individuals with chronic pain; (b) to alleviate symptoms associated with withdrawal from heroin, methadone and suboxone; and (c) for its ability to treat depression and anxiety.
Kratom use appears to be increasing in the USA (Warner et al., 2016) , especially for self-management of opioid withdrawal and pain relief (Grundmann, 2017; Prozialeck, 2016) . Pain relief appears to be the most common reason, closely followed by emotional/mental conditions such as anxiety, depression and post-traumatic stress disorder, followed by drug dependency (Grundmann, 2017) . This increase appears to be reflected in the number of calls to the National Poison Data System. The number of calls rose from 26 in 2010 to 263 in 2015 (Anwar et al., 2016) . The median age of cases was 28 years (range 2 months-69 years) and 71.7% were male. Between 2011 and 2017 about 1800 kratom exposures were reported nationally, two-thirds of these during 2016-2017 (Post et al., 2019) . By contrast, the Malaysia National Poison Center recorded only two cases of mitragynine poisonings between 2006 and 2009 (Daud et al., 2012) . Forensic toxicology investigations in cases involving NPS in the USA also indicate an increasing proportion being attributed to mitragynine. For example, one laboratory (NMS Labs) reports the proportion of its NPS blood-positive confirmations where mitragynine was identified rising from 4.7% in 2013 to 12% in 2014, and to 15.48% in the first 6 months of 2016; mitragynine was the second most frequently identified NPS during the latter period (Logan, 2016a (Logan, , 2016b .
A survey of in-patient substance users conducted in the USA during April 2017 found that 10% had used kratom in the previous 12 months and such individuals were more likely to attend Emergency Departments, and to use kratom as a replacement for heroin (64%), because of a disability or chronic pain (18%). Some 43% used it because of curiosity and a similar proportion to bypass drug tests (Smith and Lawson, 2017) . Commonly used drug screening methods do not detect kratom and its metabolites, and this may be another reason for its spreading use, to avoid positive opioid results in occupational or detoxification drug testing (Fuenffinger et al., 2017; Gunderson et al., 2014; Lesiak et al., 2014; Perrone et al., 2013; Prutipanlai et al., 2017; Warner et al., 2016) .
Legal status of kratom
The kratom plant, moreover mitragynine and its other metabolites, do not appear in any of the United Nations' drug control convention schedules. Kratom itself is regarded by the United Nations Office for Drugs and Crime (UNODC) and the EMCDDA as an NPS (EMCDDA, 2015b; UNODC, 2014) . However, it is controlled in Australia, Malaysia, Myanmar, New Zealand, Russia, South Korea, Thailand (but see below), Vietnam and in some US states. The US Food and Drug Administration (FDA) has not approved kratom. The US Drug Enforcement Agency (DEA) became so concerned about the use of kratom in the USA that on 30 August 2016 it announced it was going to place it in Schedule I of the Controlled Substances Act 1970. However, there was such an adverse reception to this news by suppliers, consumers and politicians that on 20 October 2016 the DEA withdrew the proposal and extended its public consultation process to 1 December 2016 (Henningfield et al., 2018 ) (see Discussion section). In October 2017, the FDA decided to look separately at mitragynine and 7-hydroxymitragynine (Brodwin, 2018) , and has apparently recommended that both be controlled or regulated (Swetlitz, 2018) . At the time of writing (June, 2019), it is being reported that the Department of Health and Human Services has also recommended a ban on the chemicals to the DEA (Swetlitz, 2018) . In Canada, kratom-containing products are not authorised for sale (Wang and Walker, 2018) . In Thailand the National Legislative Assembly completed its approval of a draft bill on 25 December 2018 that amends the country's Narcotic Act 1979; it came into force the day after its publication in the Government Gazette on 18 February 2019 (LawPlus Ltd, 2019) . The new regulations (Narcotics Act (No. 7) B.E. 2562 (A.D. 2019)) allow the use of cannabis and kratom for government and medical benefits, the treatment of patients, research and development, agriculture, commerce, science and industry (Sattaburuth, 2018) .
The amount of kratom seized globally in 2016 was in excess of 400 tons; this was seven times more than in the previous year (UNODC, 2018). Most was confiscated in Malaysia (399,139 tons), followed by Thailand (5,681 tons), Myanmar (1,413 tons) and Belgium (1 ton).
At the time of writing, kratom, mitragynine and 7-hydroxymitragynine are controlled in 10 EU Member States and Turkey. In the UK, kratom, and its psychoactive metabolites, is regarded by the Medicines and Healthcare products Regulatory Agency (MHRA) as a medicinal herb and would therefore require marketing authorisation for sale as a medical treatment (personal communication to lead author from MHRA, 17 May 2018). This means it is exempted from regulation under the Psychoactive Substances Act 2016, if being used by 'healthcare professionals acting in the course of their duty' or employed in approved scientific research. However, if kratom is being provided purely for its psychoactive properties prosecutions could be sought. If doctors prescribe unlicensed medicines, they need to satisfy themselves that there is sufficient safety evidence for the medicines in question. Prior to the Psychoactive Substances Act coming into force, the UK Government Chemist advised that kratom could not be considered a 'novel food' as defined in Regulation (EU) 2015/2283 (LGC, 2018). The opioid O-desmethyltramadol, which is more potent than its parent drug tramadol, was added to kratom preparations sold as 'Krypton'. This product resulted in a number of deaths (Bäckstrom et al., 2010; Kronstrand et al., 2011) . As a result, O-desmethyltramadol became controlled in the UK as a Class B drug on 26 February 2013.
Deaths associated with kratom use
Deaths associated with kratom use have been reported. Typically, the decedents had confounding health conditions and/or used other substances, whether medicines, traditional stimulants or NPS, or indeed combinations thereof, for example, propylhexedrine (Holler et al., 2011) ; loperamide (Bishop-Freeman et al., 2016) ; dextromethorphan, diphenhydramine, temazepam, clonazepam, zopiclone, citalopram, and lamotrigine (Neerman et al., 2013) ; venlafaxine, diphenhydramine and mirtazapine (McIntyre et al., 2015) ; lorazepam, triazolam, fluoxetine, quetiapine, olanzapine, pregabalin, pipamperon together with two NPS (a 'designer benzodiazepine': etizolam and a synthetic cathinone -probably 2-MMC) (Domingo et al., 2017) ; codeine, heroin, paracetamol, amphetamine, methamphetamine, MDA, MDMA and pseudoephedrine (Domingo et al., 2017) ; and quetiapine (Hughes, 2019) .
Aims of the paper
The aims of this paper are to examine the nature of deaths reported as associated with the use of kratom, to profile decedents, and contribute to the literature concerning mitragynine levels in fatal cases, whether as a direct or contributory cause (Domingo et al., 2017) . The purpose of doing so is to develop the existing limited knowledge-base, so as to inform policymakers, and potential and actual users, as well as those who may have to treat users or investigate their deaths.
Methods
Data sources for UK fatalities
In the UK context, general mortality registers (GMRs) are maintained by the national agencies responsible for collecting and analysing vital events (births, deaths, marriages and civil partnerships). This study draws on information provided by the UK GMRs as part of two EU-funded projects.
The National Programme on Substance Abuse Deaths (NPSAD) is a special mortality register that regularly receives information from coroners on a voluntary basis on deaths related to drugs in both addicts and non-addicts in England, Wales, Northern Ireland, the Channel Islands and the Isle of Man. From 2004 to 2011, information was also received from the Scottish Crime and Drug Enforcement Agency. Since 1997 details of more than 35,000 deaths have been received. To be recorded in the NPSAD database as a drug-related death, at least one of the following criteria must be met: (a) presence of one or more psychoactive substances directly implicated in death; (b) history of dependence or abuse of drugs; (c) presence of controlled drugs at post-mortem. Ethical approval is not required in the UK for studies whose subjects are deceased and solely involve retrospective reviews of death records.
A retrospective study design was employed to identify relevant cases associated with the use of kratom. Relevant cases in the UK were identified from both general and specialist mortality registers by searching the cause of death fields and post-mortem toxicological data (Scotland, Northern Ireland, NPSAD) with the following terms: 'kratom', 'mitragyna', 'mitragynine', '7-hydroxymitragynine', 'O-desmethyltramadol' and 'Krypton'. The additional fields searched on the NPSAD database were those holding data on verdict, accident details, and 'other relevant information'. Where cases were identified in the UK using the methods detailed in the section on non-UK fatalities, further details were requested and obtained from the relevant pathologists, coroners and procurator fiscals.
Data sources for non-UK fatalities
Regular searches were undertaken in English of literature databases and search engines (Google Scholar, PubMed), 'grey literature', and online media sources in Google using the aforementioned terms in conjunction with the terms 'death', 'fatality', 'mortality', 'coroner', 'inquest', 'conference', and 'abstract' to identify other cases. Google Scholar alerts were also set up using these terms. Where cases outside the UK were identified, contact with those reporting the cases (e.g. media reporters, lobby/interest groups) was made by the lead author to obtain further details. Through this process, contact was made with the US co-author who had used similar methods, including freedom of information requests, to obtain copies of coroner/medical examiner reports, including autopsy reports. Some cases were already known to the authors. The sources used for identifying each case are given in the relevant tables.
Data extraction and analyses
Key characteristics of such incidents and decedents were extracted from all available sources, with a key emphasis on accessing the official documents where possible. These details were entered into a Microsoft Office Excel spreadsheet. Characteristics of decedents were examined in terms of age, gender, ethnicity, history of drug use, employment, and living arrangements. Characteristics of deaths were examined in respect of place of death, number and combinations of post-mortem drugs, role of substances in death, manner and cause(s) of death.
Data analyses were performed using Microsoft Office Excel 2016, employing descriptive statistics for quantitative information. Data on blood, urine and other tissue (e.g. vitreous humour) concentrations are presented, where available. Qualitative information was reviewed using a content/thematic analysis approach.
Results
This study reports on a total of 156 deaths associated with the use of kratom. As far as the authors are aware, this is the largest number of cases reported on to date in the literature. Details of these individual cases are given in the supplemental spreadsheet (available online).
A total of 10 UK deaths has been identified at the time of writing (February 2019) via the methods outlined in the section on UK fatalities: eight deaths in England and two in Scotland. There have been no known deaths involving kratom or its derivatives in Northern Ireland or Wales.
Sources for non-UK cases (n = 146) identified can be broken down into four categories (a) published academic papers/ abstracts; (b) government reports; (c) media reports; and (d) reports of post-mortem toxicology casework.
The first group covering case reports of 40 deaths comprises, in order of publication year: Tungtananuwat and Lawanprasert (2010) In the second group, the DEA gives details of nine US cases (DEA, 2016b: 23-26) , and the FDA (2018a, 2018b, 2018c) provides information on 44 deaths, many of which are included in the first group above.
The third group, comprising media reports, in date order cover one Swedish case, Petersson (2010) -which also appears as case 2 in Kronstrand et al. (2011) Wing (2018a Wing ( , 2018b . One of the US media reports (Vigil, 2014 ) covers a case cited by the DEA (2016b). In addition, post-mortem toxicology results have been published by Brower et al. (2015) .
According to the Associate Medical Examiner in Arkansas, kratom was linked to the deaths of three known kratom users in the state during 2015. In two cases, kratom and other controlled substances were found in the decedents' blood. In the third case, involving a healthy male, only kratom was found in his system, the probable cause of death being ruled as kratom toxicity (Wooten, 2016) . The North Carolina Office of the Chief Medical Examiner stated that 23 individuals had died with kratom in their system, and for five it was the primary cause of death; although the period covered is unknown (Toler, 2016) . In addition, mitragynine was also found in 11 post-mortem cases examined in North Carolina . Recently, it was reported that kratom was found in the bodies of at least 27 decedents in the last 3 years in the 10 most populated counties in the state of Colorado; of these, kratom was considered to have contributed to 17 overdoses, and in at least six cases it was the only drug that contributed to death (Haarer, 2018) .
Trends and demographic characteristics
Apart from a single case reported from Thailand, all cases reported here occurred in Northwestern Europe or North America, principally the USA (Table 1 ). The first documented death occurred in 2008. The number of cases appears to have peaked in 2009-2010 (mainly due to nine Krypton cases in Sweden), and from 2013 onward there has been a steady increase in cases being reported. The majority (80.1%) of victims were male. The decedent mean age was 32.3 (range 17-64) years and, where known, all were White/Caucasian, most were employed (66.7%), and lived with someone else (77.3%).
The reasons for using kratom were not available in all cases. However, a range of reasons were noted, the main one being selfmedication, including for opiate/opioid addiction and anxiety/ stress. Recreational use and bodybuilding were also mentioned, as was using kratom to avoid positive drug tests. In the majority of cases (95.3%) it was known that the decedents had a history of drug abuse, including past or current use of kratom or Krypton (31.4%).
Characteristics of deaths
About two-thirds (66.1%) of deaths occurred at an individual's home or that of a family member or friend, but 15.2% died in a hospital or medical centre.
Tables 2a and b present information on the mitragynine and 7-hydroxymitragynine levels given in all published fatalities and those covered in this study. The key blood levels for mitragynine are: all cases (n = 71): mean 0.853, range 0.00089-16.000 mg/L; with other substances (n = 62): mean 0. 0.8903, range 00089-16.000 mg/L; and as the sole drug (n = 3): mean 0.398, range 0.0035-0.890 mg/L. The post-mortem mitragynine blood levels for four of the UK cases are above the median levels previously reported in the literature for other cases, case 3 being the highest level yet reported. The blood level for 7-hydroxymitragynine is only known for five cases: mean 0.66218, range 0.0009-2.8 mg/L. The 7-hydroxymitragynine levels for three UK cases (0.17, 0.19 and 2.8 mg/L) are all higher than the sole one (0.15 mg/L) previously reported in the literature (Karinen et al., 2014) .
In only six of all reported cases with toxicology information available (n = 129) was mitragynine the sole substance identified in the post-mortem toxicology; the ratio of mitragynine as sole mention to any mention in toxicology is 0.0465:1.0000. However, mitragynine was the sole drug implicated in 27 out of 117 cases where the cause of death is known (Table 3) ; the ratio of mitragynine as sole mention to any mention in the cause of death is 0.231:1.000. Six of these 27 cases are the same cases where mitragynine was the sole drug detected in toxicology: a ratio of 0.222:1.000. Mitragynine was detected in all but one case, that is, in 155 cases. Of these, mitragynine levels are available for 71 cases (45.8%) but unavailable/not given for 84 cases (54.2%). Mitragynine was mentioned in the cause of death for 85 (54.87%) of the 155 cases where it was detected. The substance was mentioned in the cause of death in 39/71 (54.9%) cases where levels were also stated. The main classes of other substances found can be broadly grouped into three categories: controlled/recreational drugs, therapeutic drug classes, and alcohol. Of importance is the fact that many drugs identified in these cases are central nervous system (CNS) depressants, particularly O-desmethyltramdol, other opiates/opioids, benzodiazepines and alcohol. Stimulants and therapeutic drugs used to treat anxiety, depression and psychoses were commonly found. NPS including 'designer benzodiazepines', 'designer opioids', and synthetic cathinones have also been recently reported in combination with kratom. Where known, poly substance use was found in the majority (87.2%) of cases; the average in such cases being three or four drugs (mean = 3.4, range 1-10) in addition to mitragynine/7-hydroxymitragynine. Often, combinations include opiate/opioid(s) and/or benzodiazepine(s) and/or anxiolytic(s)/anti-depressant(s)/antipsychotic(s) and/or stimulant(s).
The main cause(s) of death and autopsy findings are presented in Table 4 . The key issues emerging can be broadly assigned to five categories: (a) breathing difficulties, especially congested and/or oedematous lungs; (b) cardiac/cardio-respiratory issues; (c) brain damage/hypoxia; (d) toxic effects of kratom/Krypton (with other substances); and (e) liver/urinary problems.
The 27 deaths where the sole drug found in the post-mortem toxicology and/or implicated in deaths are summarised in Table  5 . Of note in these cases: all decedents were male and White (where ethnicity is known), with a mean age of 32 years. Where known, the majority were employed, living with someone, and had a history of drug use, including kratom.
The mean blood level of sole mitratragynine cases is about half that of all cases where levels are known, but there are only three cases where levels are available. In all cases, mitragynine/ kratom toxicity, toxic effects, overdose or intoxication is specifically mentioned in the autopsy/cause of death. Common features are pulmonary congestion and/or oedema, and other respiratory conditions; effects on the brain; cardiac/circulatory conditions/ diseases; and liver conditions. Where manner of death is known, most deaths were regarded as accidental or misadventure.
Discussion
As far as the authors are aware, this paper presents the most comprehensive summary of deaths (n = 156) linked to kratom use yet published. Only 40 of these cases have been reported previously in the scientific literature.
Trends in reporting kratom-related deaths
The number of cases being reported since 2008, both in the scientific literature and the media generally, has constantly grown. This increase in the number of deaths associated with kratom use may be due, in part, to cases being more liable to be reported as a result of increasing interest in its use by potential/actual users and the media, and therefore more active surveillance, identification and official/scientific recording. This phenomenon was observed in the UK in relation to MDMA-related fatalities following the death of Leah Betts in 1994 (Schifano et al., 2006) .
It is likely that more reports will occur as individual European countries, US states, and the federal government, become aware of the potentially fatal consequences of taking kratom or synthetic compounds containing mitragynine and its metabolite 7-hydroxymitragynine, and introduce controls on its availability. This aspect will be important to monitor, especially since the coming into force in the UK of the Psychoactive Substances Act 2016, which appears to capture kratom's psychoactive components, mitragynine and 7-hydroxymitragynine, within its scope. The Krypton-related deaths in Sweden, which also included O-desmethyltramadol in the product, led to this molecule becoming controlled in the UK (Home Office, 2013).
Increasing reports of adverse effects and toxicity including deaths associated with the use of kratom or related products led to the DEA announcing on 31 August 2016 a proposal to add mitragynine and 7-hydroxymitragynine temporarily to Schedule 1 of the 1970 Controlled Substances Act (DEA, 2016a) . This was met with many calls from interest groups for the DEA to reconsider. Following much pressure, the DEA withdrew its Notice of Intent on 13 October 2016 and opened a period of public consultation, which finished on 1 December 2016 (DEA, 2016c). The agency's consideration of representations is still awaited at the time of writing. However, at the time of writing, some six states in the USA have banned kratom.
There are likely to be other cases that have either not been identified or not reported in the scientific literature yet. For example, there has been justified criticism that the details of cases cited by the DEA in support of its proposal to schedule kratom (DEA, 2016b) are either not given at all, or key information such as toxicological levels and other key aspects are not presented. This information needs to be published whenever and wherever possible, allowing for suitable anonymity of decedents.
Some claim that no deaths have occurred in South East Asia (e.g. Singh et al., 2016) , although some have been documented (e.g. Tungtananuwat and Lawanprasert, 2010) . However, it is very likely that other deaths have occurred or are occurring there and in other parts of the world where kratom is used as a selfmedicating therapeutic agent to treat opiate/opioid dependence. There is a lack of information on drug-related poisoning deaths in Malaysia (Raj, 2017) . For all the above-mentioned reasons, and probably others such as poor identification, investigation and reporting of drug-related deaths in this region, deaths associated with kratom are likely to go unreported. To date, there is only a single case-report from Thailand (Tungtananuwat and Lawanprasert, 2010) , although mitragynine was found in the systems of two homicide victims in central Bangkok in the period 2009-2103 (Sakulsaengprapha et al., 2018) . The presence of mitragynine is not a surprise, given its widespread use in Thailand.
There is a lack of detailed published information on mortality statistics in Thailand, making it impossible to know what the true nature and extent of kratom-related deaths are in that country (personal communication to lead author from Kanlayarat Karnman, 24 June 2018). The same situation would appear to hold in Malaysia and Vietnam. Even in the UK and USA there are no accurate published national figures available.
Demographics of those dying
The cases described here share many characteristics in common with the other cases so far described in academic literature, government reports and media reports. A typical decedent is White, male, aged in their early 30s, employed who lived with someone else.
The reasons for using kratom, the use of additional substances, including CNS depressants, cause of death/autopsy findings and nature of death reflect the other cases reported. Self-medication emerged as the main reason for taking kratom, especially in connection with opiate/opioid use. Such use is common in Thailand and Malaysia (Cinosi et al., 2015) , and appears to be spreading to Western countries (Smith and Lawson, 2017) . However, its use as a recreational drug is somewhat limited; for example, it does not appear to be used be in the clubbing or music scenes (Martinotti et al., 2017; Santacroce et al., 2017) .
What is new in these cases is its link to bodybuilding and to avoid positive opiate/opioid drug tests (at work or whilst in a drug rehabilitation programme). The type(s) of kratom products and the leaves from which they have been produced are not well reported. Where such information was given in the case reports reviewed here, it would appear that the most common products were used for relaxing/pain relief and euphoric/energising effects, often in combination.
Kratom has been added as an ingredient in an energy drink promoted at large sports gatherings. Mitragynine's role as a performance-enhancing substance was added to the repertoire to be screened for at sporting events (Guddat et al., 2016) , and was added to the World Anti-Doping Agency's (WADA) 2016 Monitoring Program in January 2016 (WADA, 2015) . At the end of 2017, neither kratom nor mitragynine were listed in WADA's Anti-Doping Testing Figures reports (https://www.wada-ama.org/ en/resources/laboratories/anti-doping-testing-figures-report).
Toxicological analyses
Mitragynine and its metabolites are unlikely to be included in standard toxicology screens or routine drug testing (Philipp et al., 2011) in the near future, although increasing awareness of the use of kratom and its products may alter this situation. Tests for kratom-derived compounds are not widely available (Philipp Table 2b . Mitragynine and 7-hydroxymitragynine levels in human fatalities. , 2011) . Most toxicology laboratories need to send their samples to specialist laboratories for identification and quantification of mitragynine and 7-hydroxymitragynine (Anderson et al., 2014; Streete, 2014) . Furthermore, there are difficulties in obtaining reference samples for analysis (Holler et al., 2011) : it may be necessary to replenish purchased reference samples of mitragynine standard solution in methanol on a regular basis, even though stored as recommended, because of deterioration. This can be expensive.
In the UK context, mitragynine and/or its metabolites were detected using a basic drug screen in gas chromatography-mass spectrometry (GC-MS) and the presence and quantification of mitragynine and 7-hydroxymitragynine confirmed by liquid chromatography-mass spectrometry (LC-MS)/MS. One of the authors estimates that the limit of detection for mitragynine on the GC-MS is between 0.1 and 0.2 mg/L with their system/ extraction technique.
According to the standard reference work, Baselt et al. (2017) , the highest recorded post-mortem blood level for mitragynine is 1060 μg/L and a urine level of 3470 μg/L. There are no levels given for 7-hydroxymitragynine. Taking into account all the cases presented here with levels, the mean post-mortem blood level for mitragynine is 0.775 (range 0.00089-16.000 mg/L); the mean urine level is 1.090 (range <0.010-3.470 mg/L). For 7-hydroxymitragynine the respective mean blood and urine levels are 0.66218 (range 0.0009-2.8 mg/L) and 2.20 mg/L; however, very few levels are available for this metabolite. Where only kratom was implicated in death and/or the only substance found in post-mortem blood samples (n = 3) the following levels were reported: mean 0.398 (range 0.0035-0.890 mg/L).
There is a lack of detailed reports giving levels of mitragynine and 7-hydroxymitragynine, especially the latter, in poisoning intoxications and fatalities (Karinen et al., 2014; Neerman et al., 2013; Tungtananuwat and Lawanprasert, 2010) , and a dearth of established dosages leading to such events (Brown et al., 2017) , and safe ceiling doses for chronic consumption in humans (Kruegel and Grundmann, 2018) . Indeed, three of the known cases where 7-hydroxymitragynine levels are known were analysed by one of the present authors. Testing for 7-hydroxymitragynine is imperative, as it is typically not detectable from raw leaf consumption. Levels of mitragynine in post-mortem cases appear to be increasing, and when we see these increased levels, one could speculate that having detectable levels of 7-hydroxymitragynine could indicate a trend in consumption of extracted and/ or artificially enhanced products. Therefore, testing for, and detection of, quantifiable levels of 7-hydroxymitragynine would be helpful in checking out this theory. Brower (2015) suggests that the hydroxy metabolite could be identified via an organic bases screen; it elutes just before trazodone. One of the authors found that the metabolite elutes 0.4 min before mitragynine. It can be quantitated via LC-MS. Chromatography is also important in screening for the metabolite.
There is only a single case-report on driving under the influence of kratom (Wright, 2018) , however, mitragynine was only qualitatively detected, that is it s presence was detected but it was not qantified. Variations in the concentrations and potencies of different strains of kratom and its derivatives, as well as interindividual differences in pharmacokinetics may also be relevant factors to consider. Therefore, the publication of additional details will be of assistance to those investigating deaths where Note: Rows may sum to more than the total as more than one class of substance may have been identified; the true number of specific substances implicated in the cause of death may be higher as they have been included in cases involving 'multiple drugs' etc. DMAA: 1,3-dimethylamylamine; GHB: Gamma Hydroxybutyrate'; MDA: 3,4-Methylene dioxy amphetamine; MDMA: 3,4-Methyl enedioxy methamphetamine; NPS: Novel Psychoactive Substances; PCP: Phencyclidine; THC: Tetrahydrocannabinol; TMA: Trimethoxyamphetamine. kratom was consumed. Without such information it is very difficult to define what constitute toxic/fatal doses and post-mortem levels/concentrations, especially as there is a dearth of cases where only mitragynine and/or 7-hydroxymitragynine are identified. A balanced approach to presenting information, whether based on quantitative sources or anecdotal evidence, is required, especially in relation to reporting the adverse consequences associated with kratom use, as anecdotal evidence could carry more weight, affecting such choices (Gutierrez and Cohn, 2018) .
Cause/mechanism of death
The leading issue identified from autopsy reports is that of congested and/or oedematous lungs (Table 4) . However, such findings are very common in a high percentage of all autopsy reports. On its own, without histology and/or toxicology to confirm a kratom-related pathology, such a finding is inconclusive with respect to kratom causing death. Brain damage, principally due to hypoxia, is often seen in the cases described here, but this should be expected when the deaths involved cardio-respiratory depression, the inhalation of gases, asphyxiation (including hanging), etc. Cardiac issues also appear to be one of the key mechanisms of/contributions to death. In some cases, these appear to be known as part of a decedent's medical history, or in some instances undiagnosed and/or triggered by the consumption of a psychoactive substance, especially stimulants. The use of substances in this latter category appears to have been common, as reflected in prevalence surveys, as does their involvement in the cause of death. Liver and urinary issues are also mentioned in the cases investigated here; for some, these conditions appear to have been chronic. However, there may be a higher incidence of such findings if the autopsy results for all cases were to be made available.
An awareness of the potential contribution that underlying medical conditions, especially undiagnosed ones, may make to the risk of death is important to convey to (potential) kratom users and those treating suspected kratom overdoses/intoxications. The principal concern here would appear be that of cardiac problems, especially cardiomegaly, coronary atherosclerosis and left ventricular hypertrophy (Table 4) . Those with enlarged livers may also be at greater risk.
As with the recording and reporting of most drug-related poisoning fatalities, the actual mechanisms of death are poorly described in the cause of death fields on medical death certificates, as indeed are details of the substances themselves (Fugelstad et al., 2017; Jones and McAninch, 2015; Shai, 1994; Slavova et al., 2015) .
This situation is not peculiar to any one country or geographical region of the world; and it undermines the accurate attribution of the initial underlying incident and the actual sequence of events and processes culminating in death itself, and thus the accuracy of mortality statistics (Corkery, 2008; Shai, 1994) . This issue has been known about for decades, especially amongst those responsible for instructing doctors and others completing death certificates, for example, medical schools (Corkery, 2008; Shai, 1994 ). Yet, this problem still exists! In the UK, moves are afoot to try and mitigate these shortcomings. Since April 2019, medical examiners have started checking all death certificates issued by treating doctors for accuracy and compliance with coroner notification obligations (DHSC, 2018; Luce and Smith, 2018) .
Manner of death
Where known, the majority of deaths were 'accidental' in manner (93/131; 71%), including 'misadventure' cases (Table 1) ; for some coroners this implies that the decedent is aware that drug-taking may involve some degree of risk-taking, for others there is no distinction between that and an accident in the common-sense meaning of that term. About 9% of deaths were 'intentional', predominantly suicide, although there was one homicide. Some of the 'intentional' cases could be construed as being akin to the 'misadventure' category, whilst others where an 'open' or 'undetermined' finding was returned may have been suicide. This spread of conclusions is broadly consistent with UK findings for drug-related deaths as a whole.
Consumption of kratom and contribution to death
The adverse, intoxicating, toxic or poisoning effects of kratom and/or other substances are the dominant themes emerging from the cause of death information provided (103/117; 88%).
In 27 cases reported here, where information was available on the cause of death (n = 117), kratom alone was implicated in the cause of death used and/or found on its own. In six of these case reports mitragynine and/or 7-hydroxymitragynine was the sole substance found in the toxicology. An overview of these 27 cases is given in Table 5 . The key characteristics of the individuals who died are similar to those for all the deaths reported here: male; White; mean age of 32 years; employed; living with someone; and a history of drug use, including kratom. The principal characteristics of the deaths themselves include taking place at home address; resulting from intoxication, toxic effects, or overdose; accidental in manner; exhibiting pulmonary and/or cerebral congestion/oedema, cardiac and hepatic problems.
The majority of deaths reported here involved poly substance consumption. This echoes the patterns observed in online for a with regard to usage (Cinosi et al., 2015) . As mitragynine and its main metabolite 7-hydroxymitragynine bind to the µ and δ receptors causing an opioid-like effect at high doses and a stimulantlike effect at low doses, it is likely that they potentiate the effects of other substances consumed. The combination of kratom and stimulants (including NPS) could contribute to causing cardiac problems, whilst its use with CNS depressants (such as opioids, benzodiazepines, and alcohol mentioned in the cases reviewed here) clearly could cause potentially fatal cardio-respiratory problems. This likelihood is under-pinned by the fact that multisubstance use has been associated with a greater risk of admission to a healthcare facility and/or a serious medical outcome (Post et al., 2019) . The corollary is that using kratom on its own is likely to be safer than using it in combination with alcohol and/ or other drugs; but underlying health conditions may still be relevant in terms of risk of dying. As mitragynine appears to have a lower lethality index than heroin (King and Corkery, 2018) , its use in self-medicating for opiate/opioid dependence in countries where it is grown and produced could be seen as a de facto harmreduction activity.
The possibility of kratom-prescribed medication interactions is raised in some cases. For example, quetiapine's metabolism and clearance may be affected by mitragynine, possibly via its inhibitory effects on CYP2D6, CYP2C9 and other enzymes (Hughes, 2019) . Sertraline also appears to be potentially affected in this way as it is metabolised via CYP2D6 (Hanapi et al., 2013) . Cerebral oedema = 2; Hypoxic encephalopathy = 2; Seizures = 2; Anoxic brain injury = 1; Underlying heart condition = 1; Atherosclerosis = 1; Severe atherosclerosis = 1; Cardiomegaly = 1; Left ventricular hypertrophy = 3; Hypertensive cardiovascular disease = 1; Cardio-respiratory arrest = 2; Pulmonary oedema/congestion = 9; Pulmonary emboli = 1; Congested larynx, trachea and bronchi = 1; Aspiration of gastric contents = 2; Haemophilus influenzae and haemophilus parainfluenzae pneumonia = 1; Enlarged liver = 1; Fatty change of liver = 2; Congested liver = 1; Renal calculi = 1; Distended bladder = 1; Thyroid disease = 1; Ulcerative colitis = 1; Chronic alcoholism = 1; Mitragynine/kratom toxicity/toxic effects = 18; Mitragynine/kratom intoxication = 6; Kratom overdose = 2; Combined effects of mitragynine and 7-hydroxymitragynine = 1 Nature of death Accidental = 18 (66.7%); Misadventure = 2 (7.4%); Undetermined = 1 (3.7%); Not known = 6 (22.2%)
'At-risk' groups
The information for all cases collated in this study (see tables 1-4) suggests the possibility of seven categories of kratom users at greater risk of dying, some of which overlap:
(a) those using kratom in the context of opioid use, especially heroin, fentanyl and morphine, novel opioids (such as fentanyls, U-47700), for example for chronic pain relief; (b) those using kratom in the context of benzodiazepine use, including 'designer benzos' (such as etizolam); (c) those using kratom in the context of multiple CNS depressant drugs, especially opioids and benzodiazepines (with or without alcohol); (d) those consuming kratom in the context of recreational drug use, including stimulants (amphetamine/methamphetamine, ecstasy, cocaine), and NPS; (e) those with cardiovascular and/or hepatic medical conditions (whether diagnosed or undiagnosed), especially where stimulants are used; (f) those with psychiatric or mental health issues, such as anxiety and depression, including those taking prescribed psychiatric medicines (such as quetiapine or sertraline); and (g) those taking prescribed anti-epileptics, gabapentinoids.
A limitation of this profile of users is that it is based on deaths covered by this study, many of which have limited demographic information. However, the period is sufficiently long to see the impact of emerging NPS, especially opioids (Schifano et al., 2015) .
Strengths and limitations of this study
This is the first study to draw together information on UK kratom-related fatalities. It also presents the first comprehensive international overview and detailed analysis of cases in the public domain at the time of writing. Although most of the data are from the USA and Europe, it provides a robust dataset of nearly 160 cases from which more reliable conclusions can be drawn than hitherto. The key findings presented here echo those in a recent summary of 152 US fatalities positive for post-mortem mitragynine during July 2016-December 2017 (O'Malley Olsen et al., 2019), some of which may be included in our present study.
This study has, out of necessity, drawn on a wide range of data sources to collate information on as many kratom-related fatalities as possible, thereby facilitating the provision of a dataset that can be objectively analysed and appropriate scientific conclusions made. The quality of the data and their sources vary considerably, but the inclusion of less robust sources is justified in our opinion, as it was in studies looking at khat-related fatalities (Corkery, 2011; Corkery et al., 2011a Corkery et al., , 2011b .
In terms of a hierarchy of evidence, the present investigation and similar studies probably lie towards the bottom of the evidential pyramid. For example, using a simple four-tier approach: level 1 -generalisable studies; level 2 -conceptual studies; level 3 -descriptive studies; level 4 -single case-study (Daly et al., 2007) , some of the data used here come from levels 3 and 4. In a broader range of levels proposed by Sayre et al. (2017) : metanalysis, systematic reviews, randomised controlled clinical trials, cohort studies, case-control studies, case series/case reports, editorials and expert opinions, in vivo studies, and in vitro research studies, the data employed in the present study come from levels straddling the middle of this continuum. This present study exemplifies the need to be pragmatic in selecting approaches to research underexplored phenomena such as kratom-related fatalities. An improved database of properly collated data, as advocated, would help in moving future studies on such deaths higher up the evidential pyramid.
The specific types of sources are listed against each case in the supplemental table, together with an indication of their completeness. The level of evidence for a specific case in the present study in descending order is (a) documents relating to the incident investigation, the autopsy report and toxicology report; (b) documents relating to the incident investigation together with the autopsy report incorporating the main toxicological results; (c) summary by the coroner/medical examiner/chief investigator; (d) FDA Adverse Event Reporting System (FAERS) report; (e) published case-study; (f) published case-series; and (g) media report. That said, there is some variability in the quality in terms of completeness and consistency of sources within these categories, especially the data published by the FDA.
The documents published by the FDA (2018a, 2018b, 2018c) in support of its case to include kratom in Schedule 1 of the Controlled Substances Act 1970 largely come from FAERS. This contains entries, (a) relating to published academic papers, including many of those included in this analysis; (b) summaries of investigations by police, coroners and medical examiners that include details of autopsy and toxicology reports; as well as (c) very brief and uninformative anecdotal reports. Similar observations could be made in regard to the DEA's Three Factor Analysis (DEA, 2016b).
There is a need for measured and accurate reporting. For example, even the National Institute on Drug Abuse (NIDA) has unhelpfully concluded that 'Most kratom associated deaths appear to have resulted from adulterated products (other drugs mixed in with the kratom) or taking kratom along with other potent substances [sic] ' (NIDA, 2019) . has been added if it's the initial part that's misleading]Whilst the second clause is quite correct, the initial part of this sentence is very misleading. Such wording only serves to obfuscate scientific debate and progress.
The media, interest groups, and policymakers as well as scientists need to be as accurate as possible in presenting information and making inferences, which should be evidence-based. This can only be done through comprehensive screening and identification of cases, proper collection and accurate collation of data, especially toxicology levels, known medical history, concomitant use of other substances, and objective dissemination of information regarding deaths associated with kratom use. The exact nature of such links, if any, in terms of causality or contribution to death, including any caveats about interpretation, should be explicit. To do otherwise creates difficulties for investigating and understanding the epidemiology of such cases, and preventing future deaths. To mitigate such issues in the present paper, attempts were made to obtain copies/sight of autopsy and toxicology reports as well as police investigation reports.
Additional limitations of this paper need to be noted. Further details of cases reported in the media and conference abstracts need to be obtained to fill out the data for the cases presented here. Not all cases have necessarily been identified. However, this is believed to be the first paper where a systematic analysis of reported cases has been conducted.
Conclusion
The findings presented here add to the existing knowledge-base on deaths associated with kratom use. This paper confirms that a growing number of such fatalities is being reported, and it identifies that in most cases this is in association with the abuse of other psychoactive substances. Typically, CNS depressants including opiates/opioids, benzodiazepines and alcohol are found at postmortem, along with recreational drugs such as controlled stimulants and 'legal highs'/NPS, as well as prescribed therapeutic medications. As noted earlier, kratom was the sole drug implicated in 23.1% of cases examined here where the cause of death is known. Although the mortality data used by King and Corkery (2018) relate to England and Wales, applying their method of sole to any mention of an index drug in the cause of death, it would appear that kratom (mitragynine) has a higher lethality index than novel amphetamines, benzodiazepine analogues, cannabis, piperazines, and synthetic cathinones, but one that is lower than amphetamines, benzofurans, cocaine/crack, and other more potent substances. Underlying medical conditions, both already diagnosed or suspected as well as unknown at the time of death, can contribute to the way in which kratom takes effect and vice versa. These findings support the emerging literature about the plant.
These facts need to be taken into account by current and potential consumers of kratom, health professionals when faced with acute/chronic presentations in hospitals, and those engaged in planning prevention and treatment services. There is a need to educate health professionals, including clinicians, pathologists and medical examiners, as well as making psychiatrists and sports scientists aware of the different ways in which the plant is used.
The safety profile of Mitragynine speciosa still remains only partially understood, despite its increasing popularity. Further research is needed in respect of kratom on deaths in South East Asia where kratom is widely used; the levels of mitragynine and its metabolites consumed and possible interactions with other substances; and on toxic and fatal levels.
Above all, this study has demonstrated that without reliable, accurate and complete information that is correctly collated, scientifically analysed and disseminated in a timely manner, the phenomenon of which deaths can be ascribed to the use of kratom and the nature of any association(s) that can be made will remain unrealised.
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